Testosterone replacement therapy has also been shown to reduce circulating levels of inflammatory mediators, such as TNF-α and IL-1β as well as total cholesterol in patients with established coronary artery disease (CAD) and testosterone deficiency [7,8]. The gene discussed is IL1B; the disease is coronary artery disorder.